Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with CRT vs Surgery in Resectable ESCC
NCT07046221Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07046221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046221.